Abstract:Glioblastoma (GBM) represents a profoundly aggressive and heterogeneous brain neoplasm linked to a bleak prognosis. Hypoxia, a common feature in GBM, has been linked to tumor progression and therapy resistance. In this study, we aimed to identify hypoxia-related differentially expressed genes (DEGs) and construct a prognostic signature for GBM patients using multi-omics analysis. Patient cohorts were collected from publicly available databases, including the Gene Expression Omnibus (GEO), the Chinese Glioma Genome Atlas (CGGA), and The Cancer Genome Atlas—Glioblastoma Multiforme (TCGA-GBM), to facilitate a comprehensive analysis. Hypoxia-related genes (HRGs) were obtained from the Molecular Signatures Database (MSigDB). Differential expression analysis revealed 41 hypoxia-related DEGs in GBM patients. A consensus clustering approach, utilizing these DEGs' expression patterns, identified four distinct clusters, with cluster 1 showing significantly better overall survival. Machine learning techniques, including univariate Cox regression and LASSO regression, delineated a prognostic signature comprising six genes (ANXA1, CALD1, CP, IGFBP2, IGFBP5, and LOX). Multivariate Cox regression analysis substantiated the prognostic significance of a set of three optimal signature genes (CP, IGFBP2, and LOX). Using the hypoxia-related prognostic signature, patients were classified into high- and low-risk categories. Survival analysis demonstrated that the high-risk group exhibited inferior overall survival rates in comparison to the low-risk group. The prognostic signature showed good predictive performance, as indicated by the area under the curve (AUC) values for one-, three-, and five-year overall survival. Furthermore, functional enrichment analysis of the DEGs identified biological processes and pathways associated with hypoxia, providing insights into the underlying mechanisms of GBM. Delving into the tumor immune microenvironment, our analysis revealed correlations relating the hypoxia-related prognostic signature to the infiltration of immune cells in GBM. Overall, our study highlights the potential of a hypoxia-related prognostic signature as a valuable resource for forecasting the survival outcome of GBM patients. The multi-omics approach integrating bulk sequencing, single-cell analysis, and immune microenvironment assessment enhances our understanding of the intricate biology characterizing GBM, thereby potentially informing the tailored design of therapeutic interventions.

Retracted : Identification and validation of hypoxic markers of glioblastoma multiforme in methylation, somatic CNV characteristics based on large‐scale samples

Identification and Validation of SNHG Gene Signature to Predict Malignant Behaviors and Therapeutic Responses in Glioblastoma

Bioinformatic Analysis of Gene Expression and Methylation Regulation in Glioblastoma

Identification of glioblastoma-specific prognostic biomarkers via an integrative analysis of DNA methylation and gene expression

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis.

Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Construction of Novel DNA Methylation-Based Prognostic Model to Predict Survival in Glioblastoma

Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Integrative analysis of DNA methylation and gene expression profiles to identify biomarkers of glioblastoma

Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq

A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients with GBM.

Proteomics-based prognostic signature and nomogram construction of hypoxia microenvironment on deteriorating glioblastoma (GBM) pathogenesis

Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme

A Promising Glycolysis- and Immune-Related Prognostic Signature for Glioblastoma

Genome-wide Expression Profiling of Glioblastoma Using a Large Combined Cohort.

Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study

Identification of Methylation Immune Subtypes and Establishment of a Prognostic Signature for Gliomas Using Immune-Related Genes

Multi-omics approaches establishing histone modification based prognostic model in glioma patients and further verification of the carcinogenesis mechanism

Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma